FIELD: medicine, virology, vaccines. SUBSTANCE: invention relates to preparing living an antiinfluenza living vaccine for adults and children corresponding to an actual virus A/Nanchang/933/ 95 (H3N2) by antigenic properties. Vaccine strain A/17/ Nanchang/95/4 (H3N2) is a reassortant obtained by breeding an epidemic virus A/Nanchang/933/95 (H3N2) with cold-adapted temperature-sensitive virus A/Leningrad/134/17/57 (H2N2) as an attenuation donor. Strain is harmless for adults, its properties provide preparing reassortant vaccine strains from newly appearing epidemic viruses. Strain A/17/Nanchang/95/4 (H3N2) multiplicates actively in developing chicken embryos at optimal temperature 34 C, it shows temperature-sensitivity and cold-adaptation. Strain inherited two genes encoding surface proteins (hemagglutinin and neuraminidase) from epidemic virus and six genes encoding nonglycosylated proteins from attenuation donor. Strain A/17/Nanchang/95/4 (H3N2) is nonreactive for adults at intranasal administration and corresponds to immunogenicity indices. Vaccine strain A/17/Nanchang/95/4 (H3N2) by biological properties and nonreactivity indices corresponds to requirements for vaccine strains by Pharmacopoeia article FS 42-299 VS-89 for living antiinfluenza vaccine for intranasal use for adults. EFFECT: strain indicated above. 1 tbl, 1 ex
